Display options
Cite
Robu S, Richter A, Gosmann D, et al. Synthesis and Preclinical Evaluation of a . J Nucl Med. 2021;62(9):1228-1234doi: 10.2967/jnumed.120.258384.
Robu, S., Richter, A., Gosmann, D., Seidl, C., Leung, D., Hayes, W., Cohen, D., Morin, P., Donnelly, D. J., Lipovšek, D., Bonacorsi, S. J., Smith, A., Steiger, K., Aulehner, C., Krackhardt, A. M., & Weber, W. A. (2021). Synthesis and Preclinical Evaluation of a . Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(9), 1228-1234. https://doi.org/10.2967/jnumed.120.258384
Robu, Stephanie, et al. "Synthesis and Preclinical Evaluation of a ." Journal of nuclear medicine : official publication, Society of Nuclear Medicine vol. 62,9 (2021): 1228-1234. doi: https://doi.org/10.2967/jnumed.120.258384
Robu S, Richter A, Gosmann D, Seidl C, Leung D, Hayes W, Cohen D, Morin P, Donnelly DJ, Lipovšek D, Bonacorsi SJ, Smith A, Steiger K, Aulehner C, Krackhardt AM, Weber WA. Synthesis and Preclinical Evaluation of a . J Nucl Med. 2021 Sep 01;62(9):1228-1234. doi: 10.2967/jnumed.120.258384. Epub 2021 Jan 30. PMID: 33517324.
Copy Download .nbib Format: NLM
Share it on

J Nucl Med. 2021 Sep 01;62(9):1228-1234. doi: 10.2967/jnumed.120.258384. Epub 2021 Jan 30.

Synthesis and Preclinical Evaluation of a .

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Stephanie Robu, Antonia Richter, Dario Gosmann, Christof Seidl, David Leung, Wendy Hayes, Daniel Cohen, Paul Morin, David J Donnelly, Daša Lipovšek, Samuel J Bonacorsi, Adam Smith, Katja Steiger, Christina Aulehner, Angela M Krackhardt, Wolfgang A Weber

Affiliations

  1. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; [email protected].
  2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  3. School of Medicine, Clinic and Policlinic for Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  4. Bristol-Myers Squibb Research and Development, Princeton, New Jersey.
  5. Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.
  6. German Cancer Consortium, Munich, Germany, and German Cancer Research Center, Heidelberg, Germany; and.
  7. TranslaTUM (Zentralinstitut für translationale Krebsforschung der Technischen Universität München), Munich, Germany.

PMID: 33517324 DOI: 10.2967/jnumed.120.258384

Abstract

Blocking the interaction of the immune checkpoint molecule programmed cell death protein-1 and its ligand, PD-L1, using specific antibodies has been a major breakthrough for immune oncology. Whole-body PD-L1 expression PET imaging may potentially allow for a better prediction of response to programmed cell death protein-1-targeted therapies. Imaging of PD-L1 expression is feasible by PET with the adnectin protein

© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Keywords: 18F-BMS-986192; 68Ga-BMS-986192; 68Ga-adnectin; PD-1/PD-L1 checkpoint inhibitors; PD-L1 PET imaging

Publication Types